Cargando…
Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508237/ https://www.ncbi.nlm.nih.gov/pubmed/36151107 http://dx.doi.org/10.1038/s41467-022-33355-0 |
| _version_ | 1784796978249465856 |
|---|---|
| author | Poels, Kamrine E. Schoenfeld, Adam J. Makhnin, Alex Tobi, Yosef Wang, Yuli Frisco-Cabanos, Heidie Chakrabarti, Shaon Shi, Manli Napoli, Chelsi McDonald, Thomas O. Tan, Weiwei Hata, Aaron Weinrich, Scott L. Yu, Helena A. Michor, Franziska |
| author_facet | Poels, Kamrine E. Schoenfeld, Adam J. Makhnin, Alex Tobi, Yosef Wang, Yuli Frisco-Cabanos, Heidie Chakrabarti, Shaon Shi, Manli Napoli, Chelsi McDonald, Thomas O. Tan, Weiwei Hata, Aaron Weinrich, Scott L. Yu, Helena A. Michor, Franziska |
| author_sort | Poels, Kamrine E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9508237 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95082372022-09-25 Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer Poels, Kamrine E. Schoenfeld, Adam J. Makhnin, Alex Tobi, Yosef Wang, Yuli Frisco-Cabanos, Heidie Chakrabarti, Shaon Shi, Manli Napoli, Chelsi McDonald, Thomas O. Tan, Weiwei Hata, Aaron Weinrich, Scott L. Yu, Helena A. Michor, Franziska Nat Commun Author Correction Nature Publishing Group UK 2022-09-23 /pmc/articles/PMC9508237/ /pubmed/36151107 http://dx.doi.org/10.1038/s41467-022-33355-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Poels, Kamrine E. Schoenfeld, Adam J. Makhnin, Alex Tobi, Yosef Wang, Yuli Frisco-Cabanos, Heidie Chakrabarti, Shaon Shi, Manli Napoli, Chelsi McDonald, Thomas O. Tan, Weiwei Hata, Aaron Weinrich, Scott L. Yu, Helena A. Michor, Franziska Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer |
| title | Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer |
| title_full | Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer |
| title_fullStr | Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer |
| title_full_unstemmed | Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer |
| title_short | Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer |
| title_sort | author correction: identification of optimal dosing schedules of dacomitinib and osimertinib for a phase i/ii trial in advanced egfr-mutant non-small cell lung cancer |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508237/ https://www.ncbi.nlm.nih.gov/pubmed/36151107 http://dx.doi.org/10.1038/s41467-022-33355-0 |
| work_keys_str_mv | AT poelskamrinee authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT schoenfeldadamj authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT makhninalex authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT tobiyosef authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT wangyuli authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT friscocabanosheidie authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT chakrabartishaon authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT shimanli authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT napolichelsi authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT mcdonaldthomaso authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT tanweiwei authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT hataaaron authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT weinrichscottl authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT yuhelenaa authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer AT michorfranziska authorcorrectionidentificationofoptimaldosingschedulesofdacomitinibandosimertinibforaphaseiiitrialinadvancedegfrmutantnonsmallcelllungcancer |